Bionano Genomics, Inc. (BNGO)
NASDAQ: BNGO · Real-Time Price · USD
1.170
+0.030 (2.63%)
At close: Jun 29, 2026, 4:00 PM EDT
1.170
0.00 (0.00%)
After-hours: Jun 29, 2026, 5:51 PM EDT
Bionano Genomics Revenue
Bionano Genomics had revenue of $6.69M in the quarter ending March 31, 2026, with 3.56% growth. This brings the company's revenue in the last twelve months to $28.74M, up 0.96% year-over-year. In the year 2025, Bionano Genomics had annual revenue of $28.51M, down -7.37%.
Revenue (ttm)
$28.74M
Revenue Growth
+0.96%
P/S Ratio
0.46
Revenue / Employee
$296,268
Employees
97
Market Cap
13.43M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 28.51M | -2.27M | -7.37% |
| Dec 31, 2024 | 30.78M | -5.34M | -14.79% |
| Dec 31, 2023 | 36.12M | 8.31M | 29.90% |
| Dec 31, 2022 | 27.80M | 9.82M | 54.62% |
| Dec 31, 2021 | 17.98M | 9.48M | 111.47% |
| Dec 31, 2020 | 8.50M | -1.63M | -16.06% |
| Dec 31, 2019 | 10.13M | -1.87M | -15.59% |
| Dec 31, 2018 | 12.00M | 2.50M | 26.26% |
| Dec 31, 2017 | 9.51M | 2.71M | 39.93% |
| Dec 31, 2016 | 6.79M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Harvard Bioscience | 85.53M |
| Retractable Technologies | 37.15M |
| Precision Optics Corporation | 28.94M |
| Jin Medical International | 20.69M |
| Nephros | 19.12M |
| NEXGEL | 11.27M |
| Milestone Scientific | 8.90M |
| Lucyd | 2.98M |
BNGO News
- 5 days ago - Bionano Genomics appoints Alex Hastie as chief scientific officer - TheFly
- 5 days ago - Bionano Announces Hiring of Chief Scientific Officer - GlobeNewsWire
- 11 days ago - Bionano Genomics announces studies featuring OGM at 2026 conference - TheFly
- 11 days ago - Bionano Announces 67% Year-Over-Year Growth in Studies Featuring Optical Genome Mapping at ESHG 2026, Reflecting Expanding Global Adoption - GlobeNewsWire
- 18 days ago - Bionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders - GlobeNewsWire
- 4 weeks ago - Bionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures - GlobeNewsWire
- 4 weeks ago - Bionano Genomics announces OGM study of T-cell acute lymphoblastic leukemia - TheFly
- 4 weeks ago - Bionano Announces Largest OGM Study of T-Cell Acute Lymphoblastic Leukemia - GlobeNewsWire